MX2020004444A - Integracion genica direccionada de genes de inhibidores de nk para terapia con celulas inmunes mejorada. - Google Patents

Integracion genica direccionada de genes de inhibidores de nk para terapia con celulas inmunes mejorada.

Info

Publication number
MX2020004444A
MX2020004444A MX2020004444A MX2020004444A MX2020004444A MX 2020004444 A MX2020004444 A MX 2020004444A MX 2020004444 A MX2020004444 A MX 2020004444A MX 2020004444 A MX2020004444 A MX 2020004444A MX 2020004444 A MX2020004444 A MX 2020004444A
Authority
MX
Mexico
Prior art keywords
immune cell
cell therapy
enhanced immune
gene integration
directed gene
Prior art date
Application number
MX2020004444A
Other languages
English (en)
Spanish (es)
Inventor
Brian Busser
Philippe Duchateau
Alexandre Juillerat
Laurent Poirot
Julien Valton
Original Assignee
Cellectis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2017/076798 external-priority patent/WO2018073391A1/en
Application filed by Cellectis filed Critical Cellectis
Publication of MX2020004444A publication Critical patent/MX2020004444A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/36—Immune checkpoint inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4212—CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4217—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/73—Hydrolases (EC 3.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MX2020004444A 2017-10-19 2018-03-09 Integracion genica direccionada de genes de inhibidores de nk para terapia con celulas inmunes mejorada. MX2020004444A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2017/076798 WO2018073391A1 (en) 2016-10-19 2017-10-19 Targeted gene insertion for improved immune cells therapy
EP2018053343 2018-02-09
PCT/EP2018/055957 WO2019076486A1 (en) 2017-10-19 2018-03-09 TARGETED GENE INTEGRATION OF NK INHIBITOR GENES FOR ENHANCED IMMUNE CELL THERAPY

Publications (1)

Publication Number Publication Date
MX2020004444A true MX2020004444A (es) 2020-07-22

Family

ID=66173541

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004444A MX2020004444A (es) 2017-10-19 2018-03-09 Integracion genica direccionada de genes de inhibidores de nk para terapia con celulas inmunes mejorada.

Country Status (10)

Country Link
US (2) US12209125B2 (enExample)
EP (2) EP3684919A1 (enExample)
JP (2) JP7621795B2 (enExample)
KR (2) KR20200075851A (enExample)
CN (1) CN111511903B (enExample)
AU (2) AU2018353112B2 (enExample)
CA (1) CA3084476A1 (enExample)
IL (1) IL273828B2 (enExample)
MX (1) MX2020004444A (enExample)
WO (2) WO2019076486A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3059643A1 (en) * 2017-04-13 2018-10-18 Cellectis New sequence specific reagents targeting ccr5 in primary hematopoietic cells
AU2018311345A1 (en) * 2017-08-02 2020-02-27 Autolus Limited Cells expressing a chimeric antigen receptor or engineered TCR and comprising a nucleotide sequence which is selectively expressed
WO2019076486A1 (en) 2017-10-19 2019-04-25 Cellectis TARGETED GENE INTEGRATION OF NK INHIBITOR GENES FOR ENHANCED IMMUNE CELL THERAPY
CN112533942A (zh) 2018-06-01 2021-03-19 华盛顿大学 嵌合抗原受体细胞疗法中细胞因子释放综合征的抑制
US12378572B2 (en) * 2018-09-07 2025-08-05 Crispr Therapeutics Ag Universal donor cells
CN110055224B (zh) * 2019-04-03 2023-06-30 深圳市体内生物医药科技有限公司 一种基因修饰的免疫细胞及其制备方法和应用
EA202192975A1 (ru) 2019-04-30 2022-02-01 Криспр Терапьютикс Аг Аллогенная клеточная терапия b-клеточных злокачественных новообразований с применением генетически сконструированных т-клеток, нацеливающихся на cd19
EP3962519A1 (en) * 2019-05-01 2022-03-09 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
KR20220026586A (ko) * 2019-06-27 2022-03-04 크리스퍼 테라퓨틱스 아게 암 치료를 위한 키메라 항원 수용체 t세포 및 nk세포 억제제의 용도
US11116798B2 (en) * 2019-09-05 2021-09-14 Crispr Therapeutics Ag Universal donor cells
KR20220052370A (ko) * 2019-09-05 2022-04-27 크리스퍼 테라퓨틱스 아게 보편적 공여자 세포
EP4031654A4 (en) * 2019-09-20 2023-11-22 The University of North Carolina at Chapel Hill MODIFIED T CELLS AND METHOD FOR PRODUCING THEREOF
US20230076768A1 (en) 2020-01-14 2023-03-09 Synthekine, Inc. IL2 Orthologs and Methods of Use
KR20230024967A (ko) * 2020-06-11 2023-02-21 노파르티스 아게 Zbtb32 억제제 및 이의 용도
US20230340067A1 (en) * 2020-06-26 2023-10-26 St. Jude Children's Research Hospital, Inc. Methods of generating an activation inducible expression system in immune cells
WO2022020860A2 (en) * 2020-07-24 2022-01-27 Board Of Regents, The University Of Texas System Engineered t cells and tumor-infiltrating lymphocytes to increase tumor killing
EP3943097A1 (en) * 2020-07-24 2022-01-26 AB2 Bio SA Car-t cell therapy
EP4251746A1 (en) 2020-11-30 2023-10-04 Cellectis SA Use of aminoquinoline compounds for higher gene integration
WO2022143783A1 (en) * 2020-12-29 2022-07-07 Edigene Therapeutics (Beijing) Inc. Methods of identifying t-cell modulating genes
AU2021414617A1 (en) 2020-12-31 2023-08-10 Crispr Therapeutics Ag Universal donor cells
MX2023012760A (es) * 2021-04-30 2023-11-13 Cellectis Sa Nuevos cars anti-muc1 y celulas inmunitarias editadas geneticamente para inmunoterapia contra el cancer de tumores solidos.
JP2024527557A (ja) * 2021-07-01 2024-07-25 寧波茂行生物医薬科技有限公司 Ｂ７ｈ３を標的とする抗原結合ポリペプチド及びその応用
WO2023016514A1 (zh) * 2021-08-12 2023-02-16 苏州克睿基因生物科技有限公司 经修饰的细胞、其制备方法及应用
WO2023212566A1 (en) * 2022-04-25 2023-11-02 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for preventing t cell exhaustion
CN115820697B (zh) * 2022-09-23 2024-07-30 中国海洋大学 一种免疫细胞及其制备方法和应用
AU2024259472A1 (en) * 2023-04-20 2025-11-13 Peter Maccallum Cancer Institute Compositions and methods for immunotherapy - ii
WO2024258835A1 (en) * 2023-06-16 2024-12-19 The Trustees Of Columbia University In The City Of New York Removal of endogenous tcr chains for enhanced tcr-based immunotherapies
WO2025015130A1 (en) * 2023-07-12 2025-01-16 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Compositions and methods for the inhibition of natural killer cells

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
AU6704794A (en) 1993-04-13 1994-11-08 Sloan-Kettering Institute For Cancer Research Protection of human bone marrow from high dose antifolate therapy using mutated human dihydrofolate reductase dna
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6642043B1 (en) 1996-03-12 2003-11-04 Sloan-Kettering Institute For Cancer Research Double mutants of dihydrofolate reductase and methods of using same
EP1147209A2 (en) 1999-02-03 2001-10-24 The Children's Medical Center Corporation Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
AU2001243288B2 (en) 2000-02-24 2005-11-24 Life Technologies Corporation Simultaneous stimulation and concentration of cells
US20060153826A1 (en) 2003-01-28 2006-07-13 Sylvain Arnould Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof
WO2004083379A2 (en) 2003-03-14 2004-09-30 Walters Richard E Large volume ex vivo electroporation method
WO2011072246A2 (en) 2009-12-10 2011-06-16 Regents Of The University Of Minnesota Tal effector-mediated dna modification
WO2012098238A1 (en) * 2011-01-21 2012-07-26 Novimmune S.A. Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists
WO2012145384A1 (en) * 2011-04-20 2012-10-26 University Of Washington Through Its Center For Commercialization Beta-2 microglobulin-deficient cells
EP2855666B1 (en) 2012-05-25 2019-12-04 Cellectis Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells
US20150283233A1 (en) * 2012-06-15 2015-10-08 Gencia Corporation Compositions and Methods for Enhancing Immune Responses
CA2886684C (en) * 2012-10-10 2023-09-19 Sangamo Biosciences, Inc. T cell modifying compounds and uses thereof
JP6608807B2 (ja) * 2013-05-29 2019-11-20 セレクティス Ｒｎａガイドｃａｓヌクレアーゼ系を用いることによって免疫療法のためにｔ細胞を操作するための方法
RU2752933C2 (ru) * 2014-03-11 2021-08-11 Селлектис Способ создания т-клеток, пригодных для аллогенной трансплантации
CA2963327A1 (en) * 2014-10-07 2016-04-14 Cellectis Method for modulating car-induced immune cells activity
EP3268388A1 (en) * 2015-03-11 2018-01-17 Cellectis Methods for engineering allogeneic t cell to increase their persistence and/or engraftment into patients
CN107666828B (zh) * 2015-04-06 2021-04-09 瑞泽恩制药公司 非人动物中的人源化t细胞介导的免疫应答
CA2988854A1 (en) * 2015-05-08 2016-11-17 President And Fellows Of Harvard College Universal donor stem cells and related methods
GB2592821B (en) * 2015-07-31 2022-01-12 Univ Minnesota Modified cells and methods of therapy
US11091780B2 (en) * 2015-09-18 2021-08-17 The Regents Of The University Of California Methods for autocatalytic genome editing and neutralizing autocatalytic genome editing and compositions thereof
PT3371314T (pt) * 2015-11-04 2023-08-31 Fate Therapeutics Inc Modificação genómica de células pluripotentes
EP4012415A3 (en) * 2015-12-04 2022-12-07 Juno Therapeutics, Inc. Methods and compositions related to toxicity associated with cell therapy
CA3010869A1 (en) * 2016-01-15 2017-07-20 Etubics Corporation Methods and compositions for t-cell immunotherapy
CN109804064A (zh) * 2016-09-29 2019-05-24 南克维斯特公司 具有降低的免疫原性的hla i类缺陷的nk-92细胞
CN106636090B (zh) * 2016-10-11 2019-08-09 上海优卡迪生物医药科技有限公司 人源白细胞介素6的siRNA、重组表达CAR-T载体及其构建方法和应用
CN108148863B (zh) * 2016-12-05 2019-12-17 上海优卡迪生物医药科技有限公司 一种封闭il6r的用于缓解crs的car-t转基因载体及其构建方法和应用
WO2019076486A1 (en) 2017-10-19 2019-04-25 Cellectis TARGETED GENE INTEGRATION OF NK INHIBITOR GENES FOR ENHANCED IMMUNE CELL THERAPY

Also Published As

Publication number Publication date
JP2023055884A (ja) 2023-04-18
KR20200075851A (ko) 2020-06-26
US12209125B2 (en) 2025-01-28
EP3673049A1 (en) 2020-07-01
CN111511903B (zh) 2024-10-11
KR20250007705A (ko) 2025-01-14
US12221478B2 (en) 2025-02-11
AU2018353112A1 (en) 2020-04-23
RU2020115282A3 (enExample) 2021-11-19
EP3684919A1 (en) 2020-07-29
IL273828B1 (en) 2024-02-01
CN111511903A (zh) 2020-08-07
IL273828B2 (en) 2024-06-01
AU2018353112B2 (en) 2024-11-14
AU2018351689A1 (en) 2020-04-30
US20200237823A1 (en) 2020-07-30
WO2019076486A9 (en) 2020-05-28
CA3084476A1 (en) 2019-04-25
WO2019076486A1 (en) 2019-04-25
AU2018351689B2 (en) 2025-01-23
RU2020115282A (ru) 2021-11-19
WO2019076489A1 (en) 2019-04-25
US20200407694A1 (en) 2020-12-31
JP2020537528A (ja) 2020-12-24
JP7621795B2 (ja) 2025-01-27
IL273828A (en) 2020-05-31

Similar Documents

Publication Publication Date Title
MX2020004444A (es) Integracion genica direccionada de genes de inhibidores de nk para terapia con celulas inmunes mejorada.
MX2019004215A (es) Insercion de genes dirigida para terapia de celulas inmunes mejorada.
PL3704230T3 (pl) Proces wytwarzania kompozycji terapeutycznych z komórek zmodyfikowanych genetycznie
PH12019501959A1 (en) Therapeutic rna
ZA202108348B (en) Angiotensinogen (agt) irna compositions and methods of use thereof
PH12018500964A1 (en) Modified friedreich ataxia genes and vectors for gene therapy
MX2017014469A (es) Constructos de expresion y metodos para diseñar geneticamente levadura metilotrofica.
IL276844A (en) Interferon gene stimulator agonists and their uses
ZA201904311B (en) Cyclic dinucleotides as sting (stimulator of interferon genes) agonists
CY1121322T1 (el) Αντινοηματικο νουκλειϊκο οξυ
PH12018502048A1 (en) Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
MX2018002899A (es) Tratamiento de retinitis pigmentosa.
EA202091437A1 (ru) КОНСТРУКЦИИ ДЛЯ RNAi, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПОДАВЛЕНИЯ ЭКСПРЕССИИ PNPLA3
MX2016014129A (es) Composiciones para el control de mosquitos y usos de las mismas.
ZA201605715B (en) Cyclopropylamines as lsd1 inhibitors
PH12017501817A1 (en) Heterocyclic compounds as lsd1 inhibitors
MX377273B (es) Ciclopropilamina como inhibidor de la desmetilasa 1 específica de lisinas (lsd1).
EA201692143A1 (ru) Производные аминопиразина в качестве ингибиторов фосфатидилинозитол-3-киназы
MX2016015609A (es) Animales con dipeptidil peptidasa iv (dpp4) humanizada.
MX2017000658A (es) Citomegalovirus humano compuesto por antígenos exógenos.
SG11202008102VA (en) Cyclopentane-based modulators of sting (stimulator of interferon genes)
CA190044S (en) Portion of an insole
MX2020011470A (es) Metodos de terapia genica.
IL263059A (en) A method for treating cancer by targeting myeloid-derived suppressor cells
MX2024011757A (es) Proceso para preparar compuestos de acido carbamoiloximetil triazol ciclohexilico